Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of ($0.03), $0.20 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $30.6 million versus the consensus estimate of $29 million.

Fiscal 2025 Guidance
In 2024 Anika implemented a re-focused strategy to better align financial and human resources to deliver shareholder value. As such, Anika expects 2025 revenue ranges by segment as follows:

Commercial Channel of $47 to $49.5 million, up 12% - 18%
OEM Channel towards the lower end of the range of $64 to $68.5 million, down 12% - 18%, as a result of lower forecasts on end user pricing from J&J MedTech

The Company now expects 2025 adjusted EBITDA margin to be 8-10% compared to previously communicated low double digit adjusted EBITDA margin.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.